President and CEO Katherine Stueland stated that GeneDx achieved significant milestones in 2024, including surpassing $95 million in Q4 revenue and expanding gross margins to 70%. She highlighted the ...
Investor's Business Daily on MSN8h
Top Biotech GeneDx Catapults 48% After Obliterating Earnings ForecastsGeneDx stock catapulted Tuesday after the top-notch biotech smashed fourth-quarter expectations and issued upbeat guidance.
GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.
A new review highlights SETDB1 as a key player in osteosarcoma, promoting tumor growth, immune evasion and therapy resistance ...
News Medical on MSN12h
First insights into familial ALS in Egypt reveal genetic variations and disease progressionAmyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and eventually death.
Market OverviewThe Global Carrier Screening Market is a genetic testing process that determines whether an individual carries ...
A new review was published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback